Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of $2.80, a premium of 33% to the $2.10 price on September 26th, the day the report was issued. Medicure is a commercial-stage specialty pharmaceutical company specialized in cardiology.
